Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Check-Cap Ltd. (CHEK:NASDAQ), powered by AI.
Check-Cap Ltd. is currently trading at $1.53. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Check-Cap Ltd. on Alpha Lenz.
Check-Cap Ltd.'s P/E ratio is -0.4.
“Check-Cap Ltd. trades at a P/E of -0.4 (undervalued) with modest ROE of -226.2%.”
Ask for details →Check-Cap Ltd. is a pioneering healthcare technology company specializing in the development of innovative screening solutions for colorectal cancer. The company is renowned for its advanced capsule-based screening platform designed to detect polyps and abnormal growths in the colon. Unlike traditional methods, the Check-Cap screening platform does not require bowel preparation, thus making it a more patient-friendly alternative. Check-Cap is continuing to make strides in the healthcare industry by providing a non-invasive, radiation-free screening method, aiming to increase participation rates in colorectal cancer screening. By focusing on early detection and patient compliance, Check-Cap plays a vital role in the preventive care segment of the medical field, potentially improving patient outcomes and reducing healthcare costs associated with late-stage colorectal cancer diagnosis. Its groundbreaking technology is of significant interest to healthcare providers and regulators seeking efficient, patient-centered diagnostic solutions, highlighting its significance in the ongoing efforts to combat a major health concern worldwide.
“Check-Cap Ltd. trades at a P/E of -0.4 (undervalued) with modest ROE of -226.2%.”
Ask for details →Check-Cap Ltd. (ticker: CHEK) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 85 employees. Market cap is $9M.
The current price is $1.53 with a P/E ratio of -0.36x and P/B of -6.17x.
ROE is -226.19%.